Serving Australia’s advanced future industries
The ARC Training Centre for Facilitated Advancement of Australia’s Bioactives (FAAB) is an academia-industry consortium of leading researchers in bioactives.
About us
Our research is supported by state-of-the-art biomolecular analytical technologies and strong expertise in:
- advanced analytical science
- advanced formulations science
- biomedical and bioengineering techniques
- genomics
- glycomics
- proteomics
- microbiome analysis
- nanotechnology.
FAAB researchers are experts in bioactive identification, characterisation, manufacturing and commercial development.
We are dedicated to training the next generation of world-leading biotechnology research scientists to serve Australia’s advanced future industries.
FAAB's world-leading molecular scientists specialise in analytical, formulation and processing sciences, meeting industry needs and training future talent in the bioactive space.
We have access to a comprehensive advanced characterisation and bioanalytical facilities, including:
- ISO17025 Australian Proteome Analysis Facility (APAF) for proteomics
- Australian Genome Foundry for genomics
- resources for microbiomics, chromatography, microscopy, spectroscopy and biotechnology.
We are committed to establishing analytical validation principles and guidelines for implementing bioactives derived from natural sources, food, food-waste or cell-based biotechnology. Our multidisciplinary approach includes:
- advanced analytical sciences skills
- microbiology
- pharmacokinetics and formulation
- product provenance
- translating research in regulated environments.
All FAAB projects are grouped under three themes:
- Identifying functional bioactives – delivering advanced chemical and biological analysis and expertise.
- Enhancing bioactives – increasing understanding of bioactives to enhance potential therapeutic effectiveness.
- Delivering bioactives – utilising our specialised analytical and experimental frameworks to ensure effective delivery of bioactives, addressing challenges such as poor solubility, enhancing bioavailability, and investigating diverse matrices, formulation and administration routes.